Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype

Share :
Published: 12 Apr 2024
Views: 46
Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA

In a phase 2, two-stage study, Dr Rebecca Porter discussed the effects of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab on patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer.

The study was conducted on patients with folate receptor-α (FRα) positive recurrent microsatellite stable (MSS) / mismatch repair proficient (pMMR) serous endometrial cancer.

The findings of the study indicated that the combination of mirvetuximab soravtansine and pembrolizumab demonstrated significant activity in pre-treated patients who had a difficult-to-treat form of endometrial cancer.